Aim:In this study,we would like to determine associations between β2-Adrenergic Receptor(β2AR)polymorphisms at codon 16 and 27 and the response to short acting β2-agonist during asthmatic exacerbation.Methods:This ...Aim:In this study,we would like to determine associations between β2-Adrenergic Receptor(β2AR)polymorphisms at codon 16 and 27 and the response to short acting β2-agonist during asthmatic exacerbation.Methods:This was a prospective cross-sectional study of one year duration.One hundred and thirty two asthmatic patients were recruited.Five mls of venous blood was taken for DNA extraction and then genotyped for the β2AR polymorphisms using multiplex PCR.Patient's clinical responses to β2-agonist nebulization were then compared to their genotype to determine the association.Results:We found that there was no association between β2AR polymorphisms at both codon 16 and 27 with response towards short acting β2-agonist,P=0.315 and P=0.706 respectively.Conclusion:We suggested that β2AR polymorphisms at both codon 16 and 27 had no influent on the response to short acting β2-agonist.展开更多
基金This project was carried out under the financial support of USM short-term grant(304/PPSP/6131324)
文摘Aim:In this study,we would like to determine associations between β2-Adrenergic Receptor(β2AR)polymorphisms at codon 16 and 27 and the response to short acting β2-agonist during asthmatic exacerbation.Methods:This was a prospective cross-sectional study of one year duration.One hundred and thirty two asthmatic patients were recruited.Five mls of venous blood was taken for DNA extraction and then genotyped for the β2AR polymorphisms using multiplex PCR.Patient's clinical responses to β2-agonist nebulization were then compared to their genotype to determine the association.Results:We found that there was no association between β2AR polymorphisms at both codon 16 and 27 with response towards short acting β2-agonist,P=0.315 and P=0.706 respectively.Conclusion:We suggested that β2AR polymorphisms at both codon 16 and 27 had no influent on the response to short acting β2-agonist.
文摘目的 分析2型糖尿病(T2DM)采取长效胰岛素+口服降糖药治疗的效果。方法 96例T2DM患者,随机分为观察组和对照组,每组48例。对照组给予口服降糖药治疗,观察组给予长效胰岛素+口服降糖药治疗。比较两组患者治疗前后的血糖[糖化血红蛋白(HbA1c)、餐后2 h血糖(2 h PG)、空腹血糖(FPG)]水平、生活质量(总体健康、精力、社会功能、心理健康、躯体疼痛、躯体角色功能、情绪角色功能、躯体健康)评分以及不良反应发生情况(体重增加、低血糖)、治疗效果。结果 治疗后,观察组患者HbA1c(6.20±0.91)%、2 h PG(8.63±1.37)mmol/L、FPG(5.83±0.72)mmol/L均低于对照组的(8.34±1.15)%、(9.56±1.60)mmol/L、(7.91±1.31)mmol/L,差异具有统计学意义(P<0.05)。观察组不良反应发生率2.08%(1/48)低于对照组的14.58%(7/48),差异具有统计学意义(χ^(2)=4.909,P<0.05)。治疗后,观察组患者总体健康评分(63.25±4.48)分、精力评分(74.25±4.54)分、社会功能评分(83.67±3.91)分、心理健康评分(81.48±4.25)分、躯体疼痛评分(74.48±6.38)分、躯体角色功能评分(73.54±4.18)分、情绪角色功能评分(84.54±3.67)分、躯体健康评分(71.37±4.28)分;对照组患者总体健康评分(54.54±3.25)分、精力评分(61.22±4.01)分、社会功能评分(76.32±2.75)分、心理健康评分(61.24±3.75)分、躯体疼痛评分(66.58±4.70)分、躯体角色功能评分(61.24±4.42)分、情绪角色功能评分(73.05±2.50)分、躯体健康评分(52.31±2.76)分。观察组患者总体健康、精力、社会功能、心理健康、躯体疼痛、躯体角色功能、情绪角色功能、躯体健康评分均高于对照组,差异有统计学意义(P<0.05)。观察组治疗总有效率95.83%高于对照组的79.17%,差异具有统计学意义(P<0.05)。结论 长效胰岛素联合口服降糖药物对T2DM治疗可有效改善血糖水平,降低不良反应发生率,提升疗效。
